title: Antihyperalgesic activity of a novel synthesized analogue of lidocaine in diabetic rats.
abstract: OBJECTIVE
  The purpose of this study was to assess the antinociceptive and antihyperalgesic effects of a lidocaine analogue N-(2,6-dichlorophenyl)-2-(4-methyl-1-piperidinyl)acetamide (LIA).
  
  
  METHODS
  The structure of LIA was established by elemental analysis and compatible IR, (1) H NMR, (13) C NMR, and spectral data. Nociceptive and hyperalgesic activity were evaluated in normoglycaemic and streptozocin-induced diabetic rats using the formalin test. Formalin-evoked flinching, an indication of nociception and hyperalgesia, was increased in diabetic rats (using 0.5% formalin) compared with nondiabetic rats (using 1% formalin).
  
  
  RESULTS
  Local administration of LIA into the dorsal surface of the right hind paw (0.18-5.6 mg per paw) significantly reduced the formalin-induced nociceptive and hyperalgesic behaviour of nondiabetic and diabetic rat. The antinociceptive effect of LIA was higher than that of lidocaine injection, furthermore this effect was higher than that of gabapentin.
  
  
  CONCLUSIONS
  LIA may have potential as a treatment for diabetic hyperalgesia. Further investigations of the antinociceptive mechanisms and the safety of this new compound are necessary.
authors.affiliation: Departamento de Farmacobiología, Centro de Investigación y de Estudios Avanzados Sede Sur.
authors.forename: Liliana
authors.initials: L
authors.lastname: García-Hernández
authors.forename: Gabriel
authors.initials: G
authors.lastname: Navarrete-Vázquez
authors.forename: María Eva
authors.initials: ME
authors.lastname: González-Trujano
authors.forename: Francisco Javier
authors.initials: FJ
authors.lastname: López-Muñoz
authors.forename: Myrna
authors.initials: M
authors.lastname: Déciga-Campos
mesh_terms: D000588:Amines / Q000494:pharmacology / Q000627:therapeutic use; D000700:Analgesics / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D003509:Cyclohexanecarboxylic Acids / Q000494:pharmacology / Q000627:therapeutic use; D048909:Diabetes Complications / Q000188:drug therapy*; D003921:Diabetes Mellitus, Experimental / Q000150:complications / Q000188:drug therapy*; D005557:Formaldehyde; D000077206:Gabapentin; D006930:Hyperalgesia / Q000139:chemically induced / Q000188:drug therapy*; D008012:Lidocaine / Q000031:analogs & derivatives / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D015394:Molecular Structure; D059226:Nociceptive Pain / Q000139:chemically induced / Q000188:drug therapy; D010146:Pain / Q000139:chemically induced / Q000188:drug therapy*; D010147:Pain Measurement; D051381:Rats; D012016:Reference Values; D005680:gamma-Aminobutyric Acid / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D000588:Amines; D000700:Analgesics; D003509:Cyclohexanecarboxylic Acids; D005557:Formaldehyde; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin; D008012:Lidocaine